Purpose: To identify the spectrum of disease-causing CYP4V2 variants in Spanish patients with clinically diagnosed Bietti crystalline dystrophy (BCD) over an 8-year period and to analyse the phenotype-genotype correlation of the identified variants.
Introduction
Bietti crystalline dystrophy (BCD, MIM# 210370 ) is a progressive and inherited chorioretinal dystrophy characterized by multiple yellowish glistening crystalline retinal deposits, geographical areas of atrophy of the retinal pigment epithelium (RPE) and the choriocapillaris, choroidal sclerosis and crystalline deposits in peripheral cornea. The presence of crystalline dots has also been reported in central and paracentral cornea and in the lens epithelium (Chung et al. 2013; Garc ıa-Garc ıa et al. 2013) .
This disorder was first reported by Gian Battista Bietti in 1937 in three patients, two of whom were brothers (Bietti 1937) . Clinically, the disease manifests itself between the second and fourth decades of life and takes a progressive course. Patients develop decreased vision, nyctalopia and earlystage visual field constriction, which usually progress to marked visual impairment, peripheral visual field loss and legal blindness in the fifth and sixth decades of life (Welch 1977; Bernauer & Daicker 1992; Kaiser-Kupfer et al. 1994 ) because currently there is no available treatment for this disease. Bietti crystalline dystrophy (BCD) presents a wide phenotypic variability with patients differing in disease severity and rate of progression.
Rare CYP4V2 (MIM # 608614) variants are the only known cause of BCD. This gene maps to chromosome 4q35-qter (Jiao et al. 2000; Li et al. 2004 ) and contains 11 exons. CYP4V2 encodes a 525 amino acid hemethiolate enzyme, which is a member of the human cytochrome P450 enzymatic family .This enzyme is a fatty acid xhydroxylase of both saturated and unsaturated fatty acids (Nakano et al. 2009 ), and it is present in various human tissues including brain, placenta, heart, lungs, liver, RPE and neuroretina (Nakano et al. 2009 (Nakano et al. , 2012 . The CYP4V2 protein is mainly localized in the endoplasmic reticulum of the RPE, and it has been proposed to be involved in the physiological lipid recycling system between the RPE and photoreceptors, which is required to maintain visual function.
Functional impairment of this gene leads to the formation of crystalline intracellular fatty inclusions in retinal and other cell types, including circulating lymphocytes, corneal and conjunctiva fibroblasts, and keratinocytes (Wilson et al. 1989; Kaiser-Kupfer et al. 1994; Lee et al. 2001) .
Even though BCD is a global disease, it is reported to be common in East Asia, particularly in patients from China where the frequency of mutation has been estimated to be 0.005 (Hu 1983) . In Spain, only three cases with BCD have been reported to date, all of them living in the Mediterranean coast area (D ıaz Llopis et al. 1988; S anchez Vicente et al. 2001; Garc ıa-Garc ıa et al. 2013) .
Currently, over 60 different mutations in the CYP4V2 gene have been reported, mostly in Asian individuals, as reviewed by Ng et al. (2016) . The most common mutation in these patients is an insertion followed by a deletion at intron 6-exon 7 junction (rs207482233, c.802-8_810del17/insGC), which results in skipping of exon 7 (Ng et al. 2016) . Although all these variants are likely to result in a loss-of-function of the protein, the pathogenic mechanism that leads to the disease has not been determined. Likewise, no definitive genotype-phenotype correlations have been established because most studies have been carried out with a reduced number of patients, and in addition, a high degree of phenotypic variability is associated with BCD. The elevated clinical variability suggests that genetic and environmental factors affecting lipid metabolism, such as diet, may influence the disease manifestation and progression of BCD.
The primary aims of this study were as follows: (i) to identify the spectrum of CYP4V2 disease-causing variants in Spanish patients with a clinical diagnosis of BCD over a period of 7 years (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) and (ii) to analyse the phenotype-genotype correlation between the identified variants. As far as we know, herein we report the genotype-phenotype correlation of the largest Spanish cohort of BCD in Spain to date. Our study reveals new pathogenic CYP4V2 genotypes associated with atypical corneal manifestations.
Materials and Methods
The study protocol received approval by the General University Hospital of Alicante's Joint Committee on Clinical Research and followed the tenets of the Declaration of Helsinki. Informed consents were obtained from all the adult patients or from the guardians or parents on behalf of the children. The recruitment of all the patients with clinical diagnosis of BCD and their family members was made following a nationwide enrolment strategy over a period of 8 years (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . More than 650 public and private Spanish ophthalmological institutions and patient associations were contacted by postal letter or email to recruit patients diagnosed with BCD.
All the four participants underwent a full ophthalmic examination including best-corrected visual acuity (BCVA), slit lamp examination, in vivo corneal confocal microscopy, dilated fundus examination and fluoresceinic angiography. In vivo corneal confocal microscopy was conducted with Confoscan 3 (Nidek technologies, Gamagori, Japan). The diagnosis was made on the basis of clinical evaluation (presentation of glistening crystalline retinal deposits, geographical areas of atrophy of the RPE and the choriocapillaris, sclerosis of the choroid vessels and crystalline deposits in the peripheral cornea), after excluding other causes of crystalline dystrophy, according to the Yuzawa classification (Yuzawa et al. 1986 ).
Family members of the patients with clinical diagnosis of BCD and mutations in CYP4V2 gene were also genetically analysed.
Blood samples were collected, and genomic DNA was extracted from the peripheral leucocytes of the participant using the QIAamp DNA blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol.
Mutations in the 11 exons of CYP4V2 were analysed by direct PCR sequencing. The 11 exons of the CYP4V2 gene were amplified as previously described (Li et al. 2004 ). Terminator cycle sequencing was carried out using the BigDye (v3.1) kit (Applied Biosystems, Foster City, CA, USA), and the products of sequencing reactions were analysed in an automated capillary DNA sequencer (ABI Prism 3130-Avant genetic analyser; Applied Biosystems). Mutations were confirmed by sequencing the complementary DNA strand and by independent sequencing in a second DNA sample. Genotype-phenotype correlation in family 1 has previously been reported by our group (Garc ıa-Garc ıa et al. 2013).
Results
A total of four apparently unrelated Spanish patients with clinically diagnosed BCD were recruited for this study using a nationwide search carried out over a period of 8 years. All the patients had a negative history of consanguinity. The presence of BCD was confirmed by a detailed clinical examination. Systemic diseases such as gyrate atrophy, oxalosis, cystinosis and therapeutic use of tamoxifen or other drugs which can develop intraretinal deposits were evaluated and excluded.
Sanger sequencing revealed the presence of six different CYP4V2 coding variants in the four probands (Fig. 1) . The CYP4V2 mutations found segregated with the disease according to an autosomal recessive pattern and they were present in the homozygous state in two probands (Fig. 2 , families 1 and 2) and as compound heterozygotes in the remaining two index cases (Fig. 2 , families 3 and 4). Interestingly, two of the identified variants [p.(Ala204Thr) and p.(Arg443Trp)] were inherited as part of a unique haplotype (Fig. 2 , family 4). In addition, a total of 22 patients from these four families were also screened for the presence of CYP4V2 variants. This analysis resulted in the identification of 15 heterozygous carriers who were mainly asymptomatic, which is in accordance with the recessive nature of the disease.
Five of the variants were non-synonymous nucleotide changes and were predicted to be damaging according to PolyPhen and sorting intolerant from tolerant (SIFT) scores (Table 1) . These missense variants showed very low frequencies in the ExAC database used in this study as reference, ranging from 3 9 10 À3 to 8.2 9 10 À6 (Table 1) , and were present only in the heterozygous state. The sixth variant was a single nucleotide deletion (c.732delG) inferred to result in a frameshift and a premature stop codon in the mutant mRNA [p.(Trp244Cysfs*33)], which is predicted to be degraded by the nonsense-mediated mRNA decay pathway (Brogna & Wen 2009 ), leading to a complete loss-offunction of the enzyme. To the best of our knowledge, this variant has not previously been reported and two other identified mutations [p.(Ala204Thr) and p.(Arg443Trp)] have not previously been found in BCD patients. These results show the elevated CYP4V2 allelic heterogeneity among Spanish patients.
The clinical characteristics of the homozygous patients are summarized in Table 2 . The four probands complained of bilateral loss of vision and night blindness. The mean age was 43.75 years, ranging from 36 to 58 years, and two patients were males (50%) and two females (50%).The mean VA was 0.68 (decimal Snellen) and ranged from 0.2 to 0.9. Asymmetry between eyes in BVCA was a common finding in the participants. Slit lamp examination revealed corneal changes in three patients (75%). We have previously reported an unusual bilateral pattern of subepithelial and anterior stromal corneal crystalline deposits, with a central and paracentral distribution and no limbic affectation (subject II-3, family 1) (Garc ıa-Garc ıa et al. 2013). Similar deposits have been identified in the index cases of families 3 (subject II-2) and 4 (subject II-2), who presented with bilateral peripheral corneal crystals, but in contrast to the previous report, these deposits were also observed in the limbus of both eyes (Fig. 3) .
In addition, corneal confocal microscopy confirmed the presence of focal homogeneous crystalline subepithelial and anterior stromal corneal dots in the paracentral and midperipheral cornea of the patients II-3 (family 1), II-2 (family 3) and II-2 (family 4). The vast majority of the crystalline deposits were globular, round-edged, small in width, hyper-reflective and easy to distinguish from keratocyte nuclei. The examination of the peripheral cornea and the limbus revealed similar crystalline globular structures, but larger in size, number, shape and refringence in patients II-2 (family 3) and II-2 (family 4), located in superficial layers of the cornea. Several needleshaped deposits were also detected. The remaining corneal structures were normal. We could not demonstrate the presence of deposits in peripheral cornea and limbus of patient II-3 (family 1) and in any location of the cornea in patient II-2 (family 2). These findings are shown in Fig. 4 .
Funduscopy and fluoresceinic angiography revealed a bilateral uniform pattern of fine crystalline deposits at the posterior pole, involving several patched areas of choriocapillaris-RPE complex atrophy, without affectation of retinal midperiphery in proband II-2 (family 1), according to stage 2 in the Yuzawa classification. Probands of families 2, 3 and 4 presented a bilateral advanced degree of RPE atrophy and attenuation of the choriocapillaris throughout the fundus, with few peripheral and few refringent crystalline deposits beyond the posterior pole, in connection with stage 3 in the Yuzawa classification. These findings are shown in Fig. 5 .
Discussion
To the best of our knowledge, this study represents the largest effort to date to determine the genetic alterations underlying BCD in Spain. We recruited a total of four unrelated patients clinically diagnosed with BCD, along with 22 family members, using a nationwide enrolment conducted over an 8-year period (2009-2016) . The diagnosis of BCD in the current clinical practice in Spain is based on the family history, medical history, and thorough physical evaluation including the direct observation of changes in the retina and cornea by ophthalmoscopic and biomicroscopic procedures. Access to analysis of the CYP4V2 gene in daily practice in Spain can be difficult because it is not available in most hospitals and tends to be cumbersome and slow. Furthermore, genetic procedures are usually expensive, and the vast majority of the patients cannot afford them. Due to the fact that the clinical phenotype of BCD can be easily mistaken with late and severe stages of other diseases such as choroideremia, retinitis pigmentosa, gyrate atrophy or fundus albipunctatus, we consider genetic studies necessary to establish a reliable diagnosis of BCD.
A total of six disease-causing CYP4V2 gene variants were identified in the four probands with BCD. As far as we know, one of the variants In contrast, a previous study, carried out with 15 Italian patients, did not detect corneal deposits in any of them (Rossi et al. 2011 (Rossi et al. , 2013 . A possible explanation of this fact may be that the crystalline dots are especially subtle and are frequently overlooked even by experienced ophthalmologists. Another reason for this finding may be that the dots are clinical manifestations only linked with some specific CYP4V2 variants or only visible in the cornea at certain stages of the clinical disease, as happens with crystalline retinal dots (Yuzawa et al. 1986 ). Further studies are required to elucidate this point. Several authors (Bozkurt et al. 2010; Toto et al. 2013 ) described needleshaped and rodlike structures by corneal confocal scanning in patients with a clinical diagnosis of BCD, focusing the confocal scanning in corneal limbic area. Unfortunately, in the absence of data on the molecular analysis of the cited reports, it is not possible to establish a reliable diagnosis of BCD and link these findings to any specific CYP4V2 variant correlating phenotype and genotype. The presence of similar macroscopic and corneal confocal findings in patients with metabolic diseases like cystinosis (Cinotti et al. 2013) represents an additional risk in the clinical diagnosis of BCD. Subclinical confocal changes detected in paracentral and midperipheral corneal areas of three patients [II-3 (family 1), II-2 (family 3) and II-2 (family 4)] and additional peripheral and limbic changes found in two of them [II-2 (family 3) and II-2 (family 4)] point to a global corneal involvement in BCD and a possible centrifugal distribution of the dots, increasing in size and number from the centre to the periphery.
In family 1, we detected the missense mutation p. (Ile111Thr) in the homozygous state in the affected individual I-II 2 . This mutation has a clear Mediterranean distribution and has also been detected in several Italian (Rossi et al. 2011 (Rossi et al. , 2013 and Lebanese families (Haddad et al. 2012; Astuti et al. 2015) . It was first reported by Li et al. (Li et al. 2004) probably in a patient of European descent. This fact might indicate the existence of a founder effect and the possibility that this mutation arose in an ancestral and geographically restricted Mediterranean region. Further work is required to clarify this point. Remarkable clinical heterogeneity and variable disease progression have been observed in homozygous p.(Ile111Thr) patients, but careful phenotypic examination revealed the absence of crystalline deposits in the 360 degrees of the corneal limbus associated with this mutation. Our proband presented with subepithelial and anterior stromal corneal crystalline deposits, with a central and paracentral distribution, confirmed by confocal scanning, without limbic involvement in both eyes. The lack of confocal imaging in previous reports of this variant (Li et al. 2004; Rossi et al. 2011 Rossi et al. , 2013 Haddad et al. 2012; Astuti et al. 2015) makes it difficult to confirm whether corneal dots are associated with this mutation.
The phenotype of our homozygous p.(Ile111Thr) patient appears to be associated with a late-onset, less severe pattern of retinal dystrophy and relatively good visual acuity in both eyes. This proband shows relatively mild symptoms, and the progression of the disease seems to be slower and less aggressive than that in the other patients. A similar pattern of mild disease linked to p.(Ile111Thr) has been previously reported in two members of a Lebanese family (Haddad et al. 2012) and in an Italian proband (Rossi et al. 2011) . In contrast, three additional p.(Ile111Thr) homozygous Lebanese patients presented with a severe clinical phenotype, one of them with severe choroidal sclerosis and no crystals detectable by fundus examination at the age of 57 years (Haddad et al. 2012; Astuti et al. 2015) . These data suggest that additional environmental, genetic and/or epigenetic factors might play a role in the phenotypic variability observed in these patients.
The missense mutation p.(Arg465-Gly) was confirmed in the homozygous state in family 2, patient II-2. Previous reports have described a wide phenotypic variability associated with this mutation in the heterozygous state (Rossi et al. 2013; Halford et al. 2014) . Our homozygous patient showed a severe phenotype with a few sparkling, refractile, yellow-white deposits scattered throughout the posterior pole and extensive geographical areas of atrophy of the RPE and the choriocapillaris, with partial conservation of central retina and macular area in both eyes. Interestingly, the good visual acuity outcome in both eyes did not correlate with the magnitude of the retinal damage. This pattern of severe retinal atrophy and low number of reflective dots is usually manifested by older patients in late phases of BCD progressive disease. Patient II-2 of family 2 is a 43-year-old woman, and on the basis of this fact, we consider that the p.(Arg465Gly) mutation in the homozygous state leads to a fast rate of progression and aggressive course of the disease. Shan et al. (2005) reported that the p.(Gly95Arg) variant is inferred to produce a significant change in the polarity of the CYP4V2 protein that may contribute to disrupt the function of the enzyme. We detected this variant in two families (3 and 4) with two heterozygous and two compound heterozygous individuals. This mutation has been frequently reported in Asian patients, especially in the Chinese population (Shan et al. 2005; Lai et al. 2007; Meng et al. 2014; Yin et al. 2014) . Therefore, this variant might have arisen independently in the Spanish patients. Individual II-2 (family 3) inherited this variant from his mother and p.(Trp244Cysfs*33), which is likely to be a null allele, from his father. The combined functional defects of the two alleles in the same subject might lead to differences in the residual activity of the enzyme, explaining the clinical differences among homozygous carriers of similar inherited changes. Phenotypically, this patient showed a low number of crystals and mild patchy atrophy of the RPE and choriocapillaris. These features were asymmetric between the eyes, and the right eye presented a severe affectation of the posterior pole, according to an advanced and aggressive disease. Limbic deposits were detected in this patient by slit lamp examination, and subepithelial and anterior stromal hyper-reflective dots were observed by confocal scanning. This phenotype involves a slow but progressive generalized retinal damage associated with bilateral vision loss over the course of many years, which led to the patient's complete dependence for daily life activities at the age of 58 years.
Patient II-2 (family 4) was the youngest affected by BCD and presented an unusual compound heterozygous genotype composed of three different mutations: one of them [p.(Gly95Arg)] has been discussed earlier and the other two [p.(Ala204Thr) and p.(Arg443Trp)] were located on the same chromosome. Therefore, these two mutations formed a haplotype, acting in combination to potentially produce a severe effect on enzyme activity. This complex genotype was associated with an early-onset and aggressive pattern of retinal dystrophy progression, crystalline peripheral corneal and limbic deposits and severe vision loss compared with the other genotypes.
In summary, we have described the largest spectrum of CYP4V2 variants and phenotypic characteristics associated with BCD in Spanish patients to date. Our results show a higher prevalence of corneal crystalline changes in Spanish BCD population compared with previous studies, confirming subclinical changes by corneal confocal scanning. Molecular techniques are required for a reliable diagnosis of BCD, preventing us from failures in medical assessment or incorrect management of retinal dystrophies and metabolic diseases with similar clinical characteristics. The ultimate goal of these techniques is to obtain valuable information to treat, cure or prevent the development of BCD.
